Fosun Pharma extends subsidiary loan, outlines 2026 related party transactions

Shanghai Fosun Pharmaceutical Group announced the renewal of a loan for its controlled subsidiary, Fuyun Health, totaling 65.5 million yuan. This loan, initially provided by Fuyun Health's three shareholders, including Fosun Pharma's controlled subsidiaries Fosun Health and Ningbo Futech, and parent company Fosun High-Tech, will be extended for 12 months until December 4, 2026. The adjusted annual interest rate of 3.2% begins December 5, 2025. This renewal is within the scope of internal extensions and new entrusted loan/borrowing limits approved by the 2024 General Meeting of Shareholders.

In related developments, Fosun Pharma's board approved the renewal of ongoing related party transaction framework agreements with Fosun International for 2026. This includes product and service mutual supply, property leasing, and property services agreements. The estimated transaction limits for 2026 include sales of 30 million yuan, purchases of 25 million yuan, provision of services of 50 million yuan, and acceptance of services of 100 million yuan with Fosun International and its associates.

Additionally, Fosun Pharma plans its Second Interim General Meeting of Shareholders for December 2, 2025, to vote on the election of executive directors. The company also renewed a framework agreement with Chongqing Pharmaceutical Group, forecasting sales of 1.4 billion yuan, purchases of 50 million yuan, and service provision of 5 million yuan, and acceptance of services of 30 million yuan in 2026.